Baseline characteristics of participants in the included studies
| Study ID | Watanabe et al16 | Mangner et al17 | Landes et al18 | |
| Demographics | ||||
| Age (years) Mean (SD) or median (range) | With cancer | 83 (80–87)* | 81 (77–84) | 78.8±7.5* |
| Without cancer | 85 (82–88) | 81 (77–84) | 81.3±7.1 | |
| Male sex n (%) | With cancer | 21 (45) | 59 (59.6)* | 138 (62)* |
| Without cancer | 232 (33) | 628 (42.7) | 1135 (45) | |
| BMI (kg/m2) Mean (SD) or median (range) | With cancer | 23.6 (21.0–26.2)* | 26.6 (23.9–29.5) | 26.6±4.8* |
| Without cancer | 21.7 (19.2–24.1) | 27.4 (24.4–31.2) | 28±5.0 | |
| Diabetes mellitus n (%) | With cancer | 14 (30) | 38 (38.4) | 62 (28) |
| Without cancer | 175 (25) | 640 (43.6) | 908 (36) | |
| Hypertension n (%) | With cancer | 35 (75) | 92 (93.9) | 169 (76)* |
| Without cancer | 531 (75.6) | 1365 (93.6) | 2320 (92) | |
| Comorbidities | ||||
| Previous MI n (%) | With cancer | 5 (11) | 17 (17.3) | 29 (13) |
| Without cancer | 59 (8) | 175 (12.0) | 226 (9) | |
| PAD n (%) | With cancer | 11 (23) | 8 (8.2) | 35 (16) |
| Without cancer | 108 (15) | 171 (11.7) | 252 (14) | |
| Cerebrovascular disease n (%) | With cancer | 5 (11) | 11 (11.2) | 24 (11) |
| Without cancer | 101 (14) | 143 (9.8) | 452 (18) | |
| COPD n (%) | With cancer | 15 (32)* | 13 (13.1) | 37 (17) |
| Without cancer | 138 (20) | 248 (16.9) | 428 (17) | |
| Preprocedural parameters | ||||
| STS score (%) Mean (SD) or median (range) | With cancer | 5.4 (3.4–7.5)* | 6.0 (3.8–10.9) | 4.9±3.4* |
| Without cancer | 7.0 (4.6–9.4) | 6.7 (4.1–10.6) | 6.2±4.4 | |
| Aortic valve area (cm2) Mean (SD) or median (range) | With cancer | 0.65 (0.56–0.74) | 0.7 (0.5–0.8) | 0.72±0.22* |
| Without cancer | 0.62 (0.50–0.74) | 0.7 (0.5–0.8) | 0.65±0.20 | |
| Mean pressure gradient (mm Hg) Mean (SD) or median (range) | With cancer | 50.4 (38.8–62.1) | 44 (35–58) | 49±20 |
| Without cancer | 48.0 (36.2–59.9) | 42 (33–52) | 48±16 | |
| LVEF (%) Mean (SD) or median (range) | With cancer | 65.9 (54.0–66.4) | 57 (45–64) | 56±14 |
| Without cancer | 65.0 (59.9–70.5) | 58 (45–65) | 56±8 | |
*P<0.05 for patients with cancer compared with patients without cancer in each study.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PAD, peripheral arterial disease; STS, Society of Thoracic Surgeons.